Anti-CLDN6/Anti-CD3 Bispecific Antibody BGB-B455

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A bispecific antibody targeting both the tumor-associated antigen (TAA) claudin 6 (CLDN6; CLDN-6) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CLDN6/anti-CD3 bispecific antibody BGB-B455 targets and binds to both CLDN6 expressed on tumor cells and CD3 expressed on T-cells. This activates and redirects cytotoxic T-lymphocytes (CTLs) to CLDN6-expressing tumor cells, which leads to enhanced CTL-mediated killing of CLDN6-expressing tumor cells. CLDN6, a tight-junction protein and embryonic antigen, is overexpressed on a variety of tumor cells but is not or minimally expressed on normal, healthy adult cells.

**Synonyms:** - Anti-CLDN6/CD3 Bispecific Antibody BGB-B455 - Anti-CLDN6/CD3 T-cell Engaging Bispecific Antibody BGB-B455 - BGB B455 - BGB-B455 - BGBB455 - CLDN6 x CD3 Bispecific Antibody BGB-B455 - CLDN6/CD3 Bispecific T-cell Engager BGB-B455